Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / DiaSorin, Inc.

Approvalsnovel device granted (FDA De Novo)23 Dec 2025

DiaSorin, Inc.

23 Dec 2025: Novel device granted (FDA De Novo) · LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261). Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
23 Dec 2025
Device
LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)
Specialty
Immunology
Product Code
SGW
Country
United States
Location
Stillwater, MN
Submitted
2025-07-30
Reference
DEN250032
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at DiaSorin, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for DiaSorin, Inc. in our registers.

More in Immunology

De Novo Grants

See all

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.